Category: Dangerous Drugs

Supreme Court Agrees To Hear Generic Reglan Drug Label Suit

The U.S. Supreme Court has agreed to hear arguments over whether generic drug makers can be sued for the failure to warn about dangerous side effects on their drug label even when they follow federal rules. In PLIVA, Inc. v. Mensing a woman took metoclopramide – the generic equivalent of Reglan – for four years… read more

American Dangerous Drug Trials Being Conducted Overseas

A recent investigative article has disclosed some scary statistics. Even with FDA approval, prescription drugs kill nearly 200,000 Americans each year. As a result of consumer backlash and the raised awareness of the potential risks of dangerous drugs such as Avandia, Reglan, and Darvon/Darvocet, many U.S. drug companies have now moved their clinical trials overseas… read more

Darvon/Darvocet Pulled From The Market

Last week, the FDA finally pulled propoxyphene – sold as Darvon and Darvocet – from the U.S. market. For nearly 50 years concerns have been raised over the side effects of Darvon/Darvocet usage, including its toxicity even at low levels and its highly addictive properties. Additionally, it has not been shown to be very effective… read more

Doctors With Questionable Records Hired By Drug Companies

ProPublica, an independent news organization, has been investigating the connection between physicians and pharmaceutical companies, and how pharmaceutical company payments influence physician prescription practices, including the prescription of dangerous drugs such as Avandia, Levaquin, and Meridia. This in-depth report reveals that hundreds of doctors received payments from drug companies who had been accused of professional… read more

Can Parents Sue For A Vaccine’s Design Defect?

Last week the United States Supreme Court heard arguments concerning whether the parents of a girl who became sick shortly after being vaccinated against diphtheria, tetanus, and pertussis can sue the vaccine’s manufacturer. The parents allege a design defect. Nearly 5,000 potential lawsuits may result if the court allows the parents to sue, asserting a… read more

FDA’s Avandia Restrictions – A “Victory” For Consumer Safety

In a victory for consumers, the FDA finally restricted sales of Avandia in the United States (as well as suspending all use in Europe.) However, as noted in the New York Times, the dangers associated with Avandia only came to light after a cardiologist analyzed data from clinical trials that GlaxoSmithKline, the maker of the… read more

Avandia Clinical Trials Partially Stopped

Last week the Food and Drug Administration (FDA) advisory panel recommended that Avandia – a popular diabetes drug linked to a higher risk of heart attack – contain either stronger warning labels or restrict its use. Avandia is developed and manufactured by GlaxoSmithKline. In addition to a well-documented increased risk of heart attack, Avandia has… read more

Manufacturers of dangerous drugs should not be immune from liability

The Sixth Circuit Court of Appeals has recently submitted a question to the Food and Drug Administration requesting a response to its position on immunity. At issue is the claim by manufacturers that because the FDA regulates prescription drugs, once the drugs they make have received FDA “approval,” drug manufacturers cannot be held liable for… read more

New Reports Link Avandia To Increased Risk Of Heart Attack

This past week new studies reported that Avandia poses a substantially greater risk of heart attacks for its users. Avandia is a diabetes drug prescribed to thousands of diabetics in New Mexico and throughout the United States. In one study, published by the AMA, researchers studied more than 227,000 people who took Avandia and found… read more

DANGEROUS DRUG – Reglan

Reglan is a prescription drug pushed by pharmaceutical companies to patients to treat Gastroesophageal reflux (GER) Gastroesophageal reflux disease (GERD). Many studies dating back from the 1970s have shown that Reglan is ineffective in resolving GER and GERD. A 2006 study published in Nature Clinical Practice: Gastroenterology & Hepatology concluded that “the evidence base for… read more